← Immunovant, Inc. (IMVT) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
Immunovant, Inc. (IMVT)
Biological Products, (No Diagnostic Substances) · market cap $7.0B · as of 2026-07-12
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-11-09 (est.)
Earnings
Pipeline
6
programs
Upcoming events
1
next 90d+
Dossier
Ready
cached
Immunovant (IMVT) is a clinical-stage immunology company with 362 employees and an $8.2B market cap, built around FcRn inhibition across multiple autoimmune indications. Its lead asset IMVT-1402 is in Phase 3 for CIDP, while batoclimab (IMVT-1401) is simultaneously in Phase 3 for Thyroid Eye Disease and Generalized Myasthenia Gravis, giving the company a multi-front late-stage portfolio but also concentrated execution risk.
The catalyst path
- 2026-11-09 (est.)Earningsimp 5/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| IMVT-1402 | Phase 3 | Chronic Inflammatory Demyelinating Polyneuropathy |
| Batoclimab | Phase 3 | Thyroid Eye Disease |
| Batoclimab 680 milligrams (mg) subcutaneous (SC) weekly | Phase 2 | Chronic Inflammatory Demyelinating Polyneuropathy |
| Batoclimab 680 mg SC weekly | Phase 3 | Generalized Myasthenia Gravis |
| RVT-1401 | Phase 2 | Myasthenia Gravis |
| IMVT-1401 (batoclimab) | Phase 2 | Graves Disease |
Price & technical context
3-month
-13.3%
6-month
+34.1%
12-month
+108.7%
52-wk range
$16.08–$44.96
vs 50-day MA
-14.3%
vs 200-day MA
+6.1%
Realized vol
56.1%
Max drawdown
-60.9%
Daily closes through 2026-10-01. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for IMVT (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 6 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.